Interactive Brokers shares jump as it secures spot in S&P 500
Thursday - Needham analysts have revised the price target for Veracyte, Inc. (NASDAQ:VCYT) to $41.00, a decrease from the previous target of $51.00, while maintaining a Buy rating on the company’s stock. According to InvestingPro data, the stock currently trades at a high P/E ratio of 96.5, suggesting premium valuation despite the reduction. The firm’s stance remains optimistic about Veracyte’s prospects.
Veracyte’s first quarter of 2025 performance exceeded consensus expectations in both revenue and non-GAAP EPS. The company’s management has confirmed its revenue guidance for 2025 and has increased its adjusted EBITDA margin guidance. Although revenue growth decelerated to 18% in the first quarter of 2025 from 21% in the last quarter of 2024, this was attributed to robust sales of its Decipher and Afirma tests. InvestingPro analysis shows impressive last-twelve-month revenue growth of 23.46% and a strong gross profit margin of 69.48%.
In the midst of a competitive breast cancer diagnostics market, Veracyte is preparing to introduce the Prosigna Breast Cancer assay as a laboratory developed test (LDT) in mid-2026. Needham analysts anticipate that Veracyte’s established clinical reputation will facilitate the adoption of the new test upon its release.
The company has also reported improvements in its financial health, with a year-over-year increase of 410 basis points in non-GAAP gross margin and a 670 basis point rise in adjusted EBITDA margin. InvestingPro data confirms this strong financial position, with an excellent current ratio of 4.73 and an overall Financial Health score of "GREAT". Despite the positive operational performance, the adjustment in Veracyte’s price target to $41 from $51 is a reflection of a broader contraction in peer multiples, according to Needham’s commentary. InvestingPro subscribers have access to 12 additional ProTips and comprehensive financial metrics for deeper analysis of Veracyte’s performance.
In other recent news, Veracyte Inc . reported a strong financial performance for the first quarter of 2025, surpassing analysts’ expectations. The company achieved earnings per share (EPS) of $0.31, significantly higher than the projected $0.02, and reported revenue of $114.5 million, exceeding the anticipated $111.14 million. This reflects an 18% increase in revenue compared to the same quarter last year. Veracyte also raised its adjusted EBITDA margin guidance for 2025 to 22.5%. Additionally, the company saw a 37% growth in the volume of its Decipher prostate tests. The recent launch of the Decipher test for metastatic prostate cancer is expected to contribute further to the company’s growth. Veracyte’s strategic focus includes expanding its test offerings and enhancing its operational efficiency, as highlighted by the ongoing transition of Afirma to a new sequencing technology. The company maintains a robust balance sheet with $287 million in cash and short-term investments, positioning it well for future growth initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.